Edgewise Therapeutics

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual Congress of the World Muscle Society (WMS) with an industry-sponsored symposium and the presentation of seven scientific posters. These presentations will highlight the effects of sevasemten in individuals with Becker based on findings from the DUNE and ARCH clinical trials, as well as provide perspec.

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Edgewise Therapeutics EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

Analysts Think There's Still Time To Get In On Edgewise

Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials.

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Edgewise Therapeutics NASDAQ: EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

Analyst Think There's Still Time to Get in on Edgewise, Up 332%

Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.

EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies

Edgewise's EDG-7500 shows promise as a treatment for hypertrophic cardiomyopathy. This market is currently underserved, largely because many heart drugs can cause other cardiac problems.

Why Edgewise Therapeutics Stock Is Up 50% on Thursday

On Thursday, Edgewise Therapeutics Inc. EWTX released announced topline data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial for obstructive hypertrophic cardiomyopathy.

Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment

Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients.

Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM. In the pla.

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM on Thursday, September 19, 2024, at 8:30 am ET. The team will be joined by CIRRUS-HCM investigator, Anjali T. Owens, M.D.,.

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second quarter of 2024 and recent business highlights. “We continue to make strong progress on our cardiac and skeletal muscle programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “We look forward to sharing important updates on both our EDG-7500 and sevasemten programs over the coming months.”.

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienced management team and strong financials. Sevasemten offers a genotype-agnostic approach, competitive difference from dystrophin-targeting therapies, with potential high market valuation.

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

ACM Research

BioCryst Pharmaceuticals

Krispy Kreme

Gigacloud Tech

Dorian LPG

McEwen Mining

Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential.

7 Small-Cap Stocks to Buy for Large-Scale Gains

Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several.

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2024 and recent business highlights. “2024 is off to a great start with tremendous progress on our skeletal and cardiac muscle programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “Most recently, we initiated our Phase 2 CIRRUS-HCM trial of EDG-7500 and announced positive 2-yea.

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. “With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene.

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction. The Phase 2 trial will assess the safety, tolera.

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy (Becker) and for the treatment of Duchenne muscular dystrophy (Duchenne). Sevasemten is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage. Sevasemten is cu.

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the ARCH trial. ARCH is an open label, single-center study assessing safety, tolerability, impact on muscle damage biomarkers, pharmacokinetics (PK) and functional measures with sevasemten (EDG-5506) in adults with Becker. Sevasemten is an orally administered small molecule designed to prevent contraction-induced.

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24). EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunc.

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 2:20 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several minute.

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024, at 12:00 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several minut.

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The conference will take place at the Hilton Orlando in Orlando, FL from March 3-6, 2024. Details of the Edg.

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News for Edgewise Therapeutics Stock (EWTX)